Glaxo Ebola vax shows no adverse effects so far in first human trial

NIAID Director Dr. Anthony Fauci

With the Ebola death toll mounting in West Africa, a Phase I trial of GlaxoSmithKline's ($GSK) experimental vaccine for the disease is underway at the U.S. National Institutes of Health. And so far, health officials have no bad news to report. At a congressional hearing this week, Dr. Anthony Fauci, director of the NIH's National Institute of Allergy and Infectious Diseases (NIAID), told legislators that the study has so far produced no major side effects so far in healthy volunteers. More